177 related articles for article (PubMed ID: 38573517)
1. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials.
Lane J; Langdahl B; Stone M; Kurth A; Oates M; Timoshanko J; Wang Z; Libanati C; Cosman F
Osteoporos Int; 2024 Jul; 35(7):1195-1204. PubMed ID: 38573517
[TBL] [Abstract][Full Text] [Related]
2. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis.
Saag KG; Petersen J; Brandi ML; Karaplis AC; Lorentzon M; Thomas T; Maddox J; Fan M; Meisner PD; Grauer A
N Engl J Med; 2017 Oct; 377(15):1417-1427. PubMed ID: 28892457
[TBL] [Abstract][Full Text] [Related]
3. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
[TBL] [Abstract][Full Text] [Related]
4. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
5. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial.
Langdahl B; Hofbauer LC; Ferrari S; Wang Z; Fahrleitner-Pammer A; Gielen E; Lakatos P; Czerwinski E; Gimeno EJ; Timoshanko J; Oates M; Libanati C
Osteoporos Int; 2022 Dec; 33(12):2527-2536. PubMed ID: 36173415
[TBL] [Abstract][Full Text] [Related]
6. T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
Cosman F; Lewiecki EM; Ebeling PR; Hesse E; Napoli N; Matsumoto T; Crittenden DB; Rojeski M; Yang W; Libanati C; Ferrari S
J Bone Miner Res; 2020 Jul; 35(7):1333-1342. PubMed ID: 32445228
[TBL] [Abstract][Full Text] [Related]
7. Romosozumab Treatment in Postmenopausal Women with Osteoporosis.
Cosman F; Crittenden DB; Adachi JD; Binkley N; Czerwinski E; Ferrari S; Hofbauer LC; Lau E; Lewiecki EM; Miyauchi A; Zerbini CA; Milmont CE; Chen L; Maddox J; Meisner PD; Libanati C; Grauer A
N Engl J Med; 2016 Oct; 375(16):1532-1543. PubMed ID: 27641143
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Miller PD; Adachi JD; Albergaria BH; Cheung AM; Chines AA; Gielen E; Langdahl BL; Miyauchi A; Oates M; Reid IR; Santiago NR; Vanderkelen M; Wang Z; Yu Z
J Bone Miner Res; 2022 Aug; 37(8):1437-1445. PubMed ID: 35466448
[TBL] [Abstract][Full Text] [Related]
9. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis.
Geusens P; Feldman R; Oates M; Thomas T; Makras P; Jakob F; Langdahl B; Wang Z; Rojeski M; Libanati C
Bone; 2022 Jan; 154():116209. PubMed ID: 34547521
[TBL] [Abstract][Full Text] [Related]
10. Romosozumab: A Review in Postmenopausal Osteoporosis.
Paik J; Scott LJ
Drugs Aging; 2020 Nov; 37(11):845-855. PubMed ID: 32909197
[TBL] [Abstract][Full Text] [Related]
11. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
[TBL] [Abstract][Full Text] [Related]
12. Romosozumab followed by denosumab in Japanese women with high fracture risk in the FRAME trial.
Miyauchi A; Hamaya E; Yang W; Nishi K; Libanati C; Tolman C; Shimauchi J
J Bone Miner Metab; 2021 Mar; 39(2):278-288. PubMed ID: 33057807
[TBL] [Abstract][Full Text] [Related]
13. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
[TBL] [Abstract][Full Text] [Related]
14. Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study.
Lau EMC; Dinavahi R; Woo YC; Wu CH; Guan J; Maddox J; Tolman C; Yang W; Shin CS
Osteoporos Int; 2020 Apr; 31(4):677-685. PubMed ID: 32047951
[TBL] [Abstract][Full Text] [Related]
15. Romosozumab Efficacy in Postmenopausal Women With No Prior Fracture Who Fulfill Criteria for Very High Fracture Risk.
McClung MR; Betah D; Deignan C; Shi Y; Timoshanko J; Cosman F
Endocr Pract; 2023 Sep; 29(9):716-722. PubMed ID: 37406858
[TBL] [Abstract][Full Text] [Related]
16. 3D-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate.
Lewiecki EM; Betah D; Humbert L; Libanati C; Oates M; Shi Y; Winzenrieth R; Ferrari S; Omura F
J Bone Miner Res; 2024 May; 39(4):473-483. PubMed ID: 38477808
[TBL] [Abstract][Full Text] [Related]
17. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis.
Leder BZ; Mitlak B; Hu MY; Hattersley G; Bockman RS
J Clin Endocrinol Metab; 2020 Mar; 105(3):938-43. PubMed ID: 31674644
[TBL] [Abstract][Full Text] [Related]
18. Romosozumab and antiresorptive treatment: the importance of treatment sequence.
Cosman F; Kendler DL; Langdahl BL; Leder BZ; Lewiecki EM; Miyauchi A; Rojeski M; McDermott M; Oates MK; Milmont CE; Libanati C; Ferrari S
Osteoporos Int; 2022 Jun; 33(6):1243-1256. PubMed ID: 35165774
[TBL] [Abstract][Full Text] [Related]
19. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial.
Brown JP; Engelke K; Keaveny TM; Chines A; Chapurlat R; Foldes AJ; Nogues X; Civitelli R; De Villiers T; Massari F; Zerbini CAF; Wang Z; Oates MK; Recknor C; Libanati C
J Bone Miner Res; 2021 Nov; 36(11):2139-2152. PubMed ID: 34190361
[TBL] [Abstract][Full Text] [Related]
20. Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study.
McCloskey EV; Johansson H; Harvey NC; Lorentzon M; Shi Y; Kanis JA
Osteoporos Int; 2021 Aug; 32(8):1601-1608. PubMed ID: 33537844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
